A case of systemic allergic dermatitis caused by inhaled budesonide: cross‐reactivity in patch tests with the novel inhaled corticosteroid ciclesonide

Salava, Alexander; Alanko, Kristiina; Hyry, Heli

doi:10.1111/j.1600-0536.2012.02115.x

Cited by 7 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While systemic or topical GC often demonstrate numerous short-term benefits, significant side effects, including generalised infections, diabetes, Cushing's syndrome and osteoporosis, can limit their usage (6)(7)(8)(9)(10)(11)(12)(13). Topical GC are among the most widely used form of antiinflammatory therapy in dermatology, but physicians also often are reluctant to deploy them due to their atrophogenic side effects, including skin hypopigmentation, telangiectasia, delayed wound healing and impaired cutaneous innate immunity (14)(15)(16)(17)(18)(19). GC also induce side effects on the epidermis, including defects in epidermal structure (thinning) and permeability barrier function, which can be attributed, in large part, to an inhibition of epidermal proliferation, differentiation and lipid production (20)(21)(22)(23).…”

Section: Introductionmentioning

confidence: 99%

Topical hesperidin prevents glucocorticoid‐induced abnormalities in epidermal barrier function in murine skin

Man

Mauro

Kim

et al. 2014

Experimental Dermatology

View full text Add to dashboard Cite

Systemic and topical glucocorticoids (GC) can cause significant adverse effects not only on the dermis, but also on epidermal structure and function. In epidermis, a striking GC-induced alteration in permeability barrier function occurs that can be attributed to an inhibition of epidermal mitogenesis, differentiation and lipid production. As prior studies in normal hairless mice demonstrated that topical applications of a flavonoid ingredient found in citrus, hesperidin, improve epidermal barrier function by stimulating epidermal proliferation and differentiation, we assessed here whether its topical applications could prevent GC-induced changes in epidermal function in murine skin and the basis for such effects. When hairless mice were co-treated topically with GC and 2% hesperidin twice-daily for 9 days, hesperidin co-applications prevented the expected GC-induced impairments of epidermal permeability barrier homoeostasis and stratum corneum (SC) acidification. These preventive effects could be attributed to a significant increase in filaggrin expression, enhanced epidermal β-glucocerebrosidase activity and accelerated lamellar bilayer maturation, the last two likely attributable to a hesperidin-induced reduction in stratum corneum pH. Furthermore, co-applications of hesperidin with GC largely prevented the expected GC-induced inhibition of epidermal proliferation. Finally, topical hesperidin increased epidermal glutathione reductase mRNA expression, which could counteract multiple functional negative effects of GC on epidermis. Together, these results show that topical hesperidin prevents GC-induced epidermal side effects by divergent mechanisms.

show abstract

Section: Introductionmentioning

confidence: 99%

Topical hesperidin prevents glucocorticoid‐induced abnormalities in epidermal barrier function in murine skin

Man

Mauro

Kim

et al. 2014

Experimental Dermatology

View full text Add to dashboard Cite

show abstract

“…Für die Zukunft wurde empfohlen, keine Kortikosteroide der Gruppe B (Acetonidderivate) mehr zu verwenden, die anderen Gruppen A, C und D wurden freigegeben 4 . Ein ähnlich gelagerter Fall mit einer systemischen Kontaktdermatitis auf Budesonid mit einer Kreuzreaktion auf Ciclesonid wurde berichtet 5 .…”

Section: Konsequenzen Für Die Patientenunclassified

Kleine Ursache – große Wirkung: Spättyp-Hauttests mit Medikamenten als Auslöser von disseminierten Rezidivexanthemen

Bircher

Jamiolkowski

Steveling

et al. 2022

Aktuelle Dermatologie

View full text Add to dashboard Cite

ZusammenfassungEs werden zwei Patienten vorgestellt, die wegen eines streuenden allergischen Kontakt- bzw. Arzneimittelexanthems auf Budesonid bzw. Antibiotika abgeklärt wurden. Bei beiden trat innerhalb einiger Stunden nach Anlegen eines Epikutantests mit Budesonid bzw. Intradermaltesten mit Amoxicillin eine stark positive Hauttestreaktion sowie ein Exanthem auf. Beim ersten Patienten lag eine Sensibilisierung auf die kreuzreagierenden Moleküle Budesonid und Amcinonid, bei der zweiten Patientin eine ausgeprägte Überempfindlichkeit auf Aminopenizilline vor. Aufflammphänomene (Flare-ups) sind v. a. aus der Kontaktallergologie bekannt, können aber auch bei der Abklärung von allergischen Arzneimittelexanthemen auftreten. Systemische Reaktionen vom verzögerten Typ auf Spättyp-Hauttests mit Medikamenten sind relativ selten, können aber eine erhebliche Morbidität bewirken. Verschiedene Formen von Aufflammphänomenen in der Allergologie werden diskutiert.

show abstract

Contact Allergy to Topical Drugs

Goossens¹,

Gonçalo²

2020

Contact Dermatitis

View full text Add to dashboard Cite

A case of systemic allergic dermatitis caused by inhaled budesonide: cross‐reactivity in patch tests with the novel inhaled corticosteroid ciclesonide

Cited by 7 publications

References 9 publications

Topical hesperidin prevents glucocorticoid‐induced abnormalities in epidermal barrier function in murine skin

Topical hesperidin prevents glucocorticoid‐induced abnormalities in epidermal barrier function in murine skin

Kleine Ursache – große Wirkung: Spättyp-Hauttests mit Medikamenten als Auslöser von disseminierten Rezidivexanthemen

Contact Allergy to Topical Drugs

Contact Info

Product

Resources

About